Literature DB >> 27586169

Long-Term Echocardiographic Outcome in Super-Responders to Cardiac Resynchronization Therapy and the Association With Mortality and Defibrillator Therapy.

Aafke C van der Heijden1, Ulas Höke1, Joep Thijssen1, C Jan Willem Borleffs1, Ron Wolterbeek2, Martin J Schalij1, Lieselot van Erven3.   

Abstract

Super-response to cardiac resynchronization therapy (CRT) is associated with significant left ventricular (LV) reverse remodeling and improved clinical outcome. The study aimed to: (1) evaluate whether LV reverse remodeling remains sustained during long-term follow-up in super-responders and (2) analyze the association between the course of LV reverse remodeling and ventricular arrhythmias. Of all, primary prevention super-responders to CRT were selected. Super-response was defined as LV end-systolic volume reduction of ≥30% 6 months after device implantation. Cox regression analysis was performed to investigate the association of LV ejection fraction (LVEF) as time-dependent variable with implantable-cardioverter defibrillator (ICD) therapy and mortality. A total of 171 super-responders to CRT-defibrillator were included (mean age 67 ± 9 years; 66% men; 37% ischemic heart disease). Here of 129 patients received at least 1 echocardiographic evaluation after a median follow-up of 62 months (25th to 75th percentile, 38 to 87). LV end-diastolic volume, LV end-systolic volume, and LVEF after 6-month follow-up were comparable with those after 62-month follow-up (p = 0.90, p = 0.37, and p = 0.55, respectively). Changes in LVEF during follow-up in super-responders were independently associated with appropriate ICD therapy (hazard ratio 0.94, 95% CI 0.90 to 0.98; p = 0.005) and all-cause mortality (hazard ratio 0.95, 95% CI 0.91 to 1.00; p = 0.04). A 5% increase in LVEF was associated with a 1.37 times lower risk of appropriate ICD therapy and a 1.30 times lower risk of mortality. In conclusion, LV reverse remodeling in super-responders to CRT remains sustained during long-term follow-up. Changes in LVEF during follow-up were associated with mortality and ICD therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27586169     DOI: 10.1016/j.amjcard.2016.07.041

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Does 'super-responder' patients to cardiac resynchronization therapy still have indications for neuro-hormonal antagonists? Evidence from long-term follow-up in a single center.

Authors:  Yi-Ran Hu; Wei Hua; Han Jin; Min Gu; Xiao-Han Fan; Hong-Xia Niu; Li-Gang Ding; Jing Wang; Shu Zhang
Journal:  J Geriatr Cardiol       Date:  2019-03       Impact factor: 3.327

2.  Impact of corticosteroid use on the clinical response and prognosis in patients with cardiac sarcoidosis who underwent an upgrade to cardiac resynchronization therapy.

Authors:  Yuya Suzuki; Mitsuru Takami; Koji Fukuzawa; Kunihiko Kiuchi; Akira Shimane; Jun Sakai; Toshihiro Nakamura; Atsusuke Yatomi; Yusuke Sonoda; Hiroyuki Takahara; Kazutaka Nakasone; Kyoko Yamamoto; Ken-Ichi Tani; Hidehiro Iwai; Yusuke Nakanishi; Ken-Ichi Hirata
Journal:  J Arrhythm       Date:  2022-03-17

3.  Echocardiographic markers of dyssynchrony as predictors of super-response to cardiac resynchronisation therapy - a pilot study.

Authors:  V A Kuznetsov; A M Soldatova; J D Kasprzak; D V Krinochkin; N N Melnikov
Journal:  Cardiovasc Ultrasound       Date:  2018-10-02       Impact factor: 2.062

4.  Cardiac electrical and mechanical synchrony of super-responders to cardiac resynchronization therapy.

Authors:  Ke-Bei Li; Zhi-Yong Qian; Xue-Song Qian; Yong Zhou; Di-Di Zhu; Yuan-Hao Qiu; Yao Wang; Xiao-Feng Hou; Jian-Gang Zou; Yu-Feng Sheng
Journal:  Chin Med J (Engl)       Date:  2020-01-20       Impact factor: 2.628

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.